Pub Date : 2026-01-06DOI: 10.1016/j.jdin.2025.12.011
Hyun Jung Kim MPH, PhD , Hei Sung Kim MD, PhD
{"title":"Maternal vitiligo is associated with increased autoimmune and atopic disease in offspring: A nationwide birth cohort study","authors":"Hyun Jung Kim MPH, PhD , Hei Sung Kim MD, PhD","doi":"10.1016/j.jdin.2025.12.011","DOIUrl":"10.1016/j.jdin.2025.12.011","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"25 ","pages":"Pages 41-43"},"PeriodicalIF":5.2,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-05DOI: 10.1016/j.jdin.2025.12.012
López Di Noto Ada Laura MD, Torre Ana Clara MD, Cura María Julia MD, Mazzuoccolo Luis Daniel MD
{"title":"Real-world vitiligo management in Argentina: Bridging guidelines and practice","authors":"López Di Noto Ada Laura MD, Torre Ana Clara MD, Cura María Julia MD, Mazzuoccolo Luis Daniel MD","doi":"10.1016/j.jdin.2025.12.012","DOIUrl":"10.1016/j.jdin.2025.12.012","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"25 ","pages":"Pages 18-19"},"PeriodicalIF":5.2,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-29DOI: 10.1016/j.jdin.2025.11.030
Talia Thomas BS , Luke Moore BS, MBTS , Angela Moore MD
{"title":"Role of scratches and mat hygiene in wrestling-associated skin infections","authors":"Talia Thomas BS , Luke Moore BS, MBTS , Angela Moore MD","doi":"10.1016/j.jdin.2025.11.030","DOIUrl":"10.1016/j.jdin.2025.11.030","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"25 ","pages":"Pages 20-21"},"PeriodicalIF":5.2,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-26DOI: 10.1016/j.jdin.2025.12.008
Rachel Granovsky MSc, BA , Allison Bai BA , Ilona Ponyatyshyn BA , Zhuoqing Suzy Gellatly MS, BA , Jatin Narang MS, MD , Gabriela Cobos MD
{"title":"GLP-1 receptor agonist use in patients with psoriasis or hidradenitis suppurativa","authors":"Rachel Granovsky MSc, BA , Allison Bai BA , Ilona Ponyatyshyn BA , Zhuoqing Suzy Gellatly MS, BA , Jatin Narang MS, MD , Gabriela Cobos MD","doi":"10.1016/j.jdin.2025.12.008","DOIUrl":"10.1016/j.jdin.2025.12.008","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"25 ","pages":"Pages 8-10"},"PeriodicalIF":5.2,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-26DOI: 10.1016/j.jdin.2025.12.010
Mariona Oliver MD , Jannik Rousel PhD , Jan W. Schoones MSc , Hanna Niehues PhD , Ilse van Ee MSc , Jorien Versteeg MSc , Jim van der Zon MSc , Sebastian J.V. Pruijn MSc , Martijn B.A. van Doorn MD, PhD , Deepak M.W. Balak MD, PhD , Robert Rissmann PhD , Vasileios Exadaktylos PhD , The Next Generation Immuno Dermatology Consortium (NGID)
{"title":"Remote monitoring in chronic immune-mediated inflammatory diseases: A systematic review of active and passive approaches","authors":"Mariona Oliver MD , Jannik Rousel PhD , Jan W. Schoones MSc , Hanna Niehues PhD , Ilse van Ee MSc , Jorien Versteeg MSc , Jim van der Zon MSc , Sebastian J.V. Pruijn MSc , Martijn B.A. van Doorn MD, PhD , Deepak M.W. Balak MD, PhD , Robert Rissmann PhD , Vasileios Exadaktylos PhD , The Next Generation Immuno Dermatology Consortium (NGID)","doi":"10.1016/j.jdin.2025.12.010","DOIUrl":"10.1016/j.jdin.2025.12.010","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"25 ","pages":"Pages 22-24"},"PeriodicalIF":5.2,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-24DOI: 10.1016/j.jdin.2025.12.006
Aya Youssef BS , Yeon Joo Kim MD, PhD , Brandon Smith MD , Joe K. Tung MD, MBA
{"title":"Adults with a history of melanoma have higher odds of laryngeal cancer in the United States","authors":"Aya Youssef BS , Yeon Joo Kim MD, PhD , Brandon Smith MD , Joe K. Tung MD, MBA","doi":"10.1016/j.jdin.2025.12.006","DOIUrl":"10.1016/j.jdin.2025.12.006","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"25 ","pages":"Pages 11-13"},"PeriodicalIF":5.2,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Eye involvement in a series of 94 young patients with congenital ichthyosis: Importance of early ophthalmological referral","authors":"Natalia Blanco-Calvo MD , Antonio Núñez-Reiz MD , Isabel Vals-Ferrán MD , Raman Malhotra MD , Angela Hernández-Martín MD","doi":"10.1016/j.jdin.2025.12.004","DOIUrl":"10.1016/j.jdin.2025.12.004","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"25 ","pages":"Pages 25-27"},"PeriodicalIF":5.2,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1016/j.jdin.2025.09.022
Kristina Callis Duffin MD, MS , Christopher E.M. Griffiths MD, FMedSci , Matthias Hoffmann MD , Andrew Blauvelt MD, MBA , Yevgeniy Balagula MD , Andrew Napoli PhD , Brandon Becker PhD, MPH , Ying-Ming Jou PhD , Rachel Dyme MD , Virginia Hala BS , Andreas Pinter MD , Diamant Thaçi MD , Linda Stein Gold MD , Mark Lebwohl MD
Background
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in multiple countries for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Objective
The 52-week, phase 3b/4 PSORIATYK SCALP (NCT05478499) trial evaluated deucravacitinib efficacy and safety in scalp psoriasis, including patients with more limited overall psoriasis. Here, we report week 16 results.
Methods
Adults with moderate to severe scalp psoriasis and body surface area involvement ≥ 3% were randomized 1:2 to placebo (n = 51) or deucravacitinib 6 mg once daily (n = 103) through week 16. The primary efficacy endpoint was scalp-specific Physician Global Assessment score of 0/1; key secondary endpoints were Psoriasis Scalp Severity Index 90, scalp-specific numeric rating scale itch score, and static Physician Global Assessment (sPGA) 0/1.
Results
In the overall population, scalp-specific Physician Global Assessment score of 0/1 (48.5% vs 13.7%; P < .0001), Psoriasis Scalp Severity Index 90 (38.8% vs 2.0%; P < .0001), and mean change from baseline in scalp-specific numeric rating scale itch (−3.2 vs −0.7; P < .0001) were superior with deucravacitinib versus placebo. In the sPGA ≥ 3 subpopulation, sPGA 0/1 was superior with deucravacitinib (51.0% vs 4.3%; P < .0001). Adverse events were comparable between groups.
Limitations
16-week analysis.
Conclusion
Deucravacitinib was efficacious and well tolerated in patients with moderate to severe scalp psoriasis.
deucravacitinib是一种口服、选择性、变质酪氨酸激酶2抑制剂，已在多个国家被批准用于治疗中度至重度斑块性银屑病的成人患者，这些患者是全身治疗的候选者。这项为期52周的3b/4期PSORIATYK头皮（NCT05478499）试验评估了deucravacitinib治疗头皮牛皮癣的有效性和安全性，包括更有限的全面性牛皮癣患者。在这里，我们报告第16周的结果。方法中度至重度头皮银屑病且体表受累≥3%的成年人，以1:2的比例随机分为安慰剂组（n = 51）或deucravacitinib组（n = 103），每日1次，至第16周。主要疗效终点为头皮特异性医师整体评估评分0/1；关键次要终点是牛皮癣头皮严重程度指数90，头皮特异性数字评定量表瘙痒评分和静态医师整体评估（sPGA） 0/1。结果在总体人群中，deucravacitinib优于安慰剂，头皮特异性医师全球评估评分为0/1 (48.5% vs 13.7%; P < 0.0001)，牛皮癣头皮严重性指数90 (38.8% vs 2.0%; P < 0.0001)，头皮特异性数字评定量表瘙痒的平均基线变化（- 3.2 vs - 0.7; P < 0.0001）。在sPGA≥3亚群中，deucravacitinib优于sPGA 0/1 （51.0% vs 4.3%; P < .0001）。两组间不良事件具有可比性。Limitations16-week分析。结论deucravacitinib治疗中重度头皮银屑病疗效确切，耐受性良好。
{"title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)","authors":"Kristina Callis Duffin MD, MS , Christopher E.M. Griffiths MD, FMedSci , Matthias Hoffmann MD , Andrew Blauvelt MD, MBA , Yevgeniy Balagula MD , Andrew Napoli PhD , Brandon Becker PhD, MPH , Ying-Ming Jou PhD , Rachel Dyme MD , Virginia Hala BS , Andreas Pinter MD , Diamant Thaçi MD , Linda Stein Gold MD , Mark Lebwohl MD","doi":"10.1016/j.jdin.2025.09.022","DOIUrl":"10.1016/j.jdin.2025.09.022","url":null,"abstract":"<div><h3>Background</h3><div>Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in multiple countries for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.</div></div><div><h3>Objective</h3><div>The 52-week, phase 3b/4 PSORIATYK SCALP (NCT05478499) trial evaluated deucravacitinib efficacy and safety in scalp psoriasis, including patients with more limited overall psoriasis. Here, we report week 16 results.</div></div><div><h3>Methods</h3><div>Adults with moderate to severe scalp psoriasis and body surface area involvement ≥ 3% were randomized 1:2 to placebo (<em>n</em> = 51) or deucravacitinib 6 mg once daily (<em>n</em> = 103) through week 16. The primary efficacy endpoint was scalp-specific Physician Global Assessment score of 0/1; key secondary endpoints were Psoriasis Scalp Severity Index 90, scalp-specific numeric rating scale itch score, and static Physician Global Assessment (sPGA) 0/1.</div></div><div><h3>Results</h3><div>In the overall population, scalp-specific Physician Global Assessment score of 0/1 (48.5% vs 13.7%; <em>P</em> < .0001), Psoriasis Scalp Severity Index 90 (38.8% vs 2.0%; <em>P</em> < .0001), and mean change from baseline in scalp-specific numeric rating scale itch (−3.2 vs −0.7; <em>P</em> < .0001) were superior with deucravacitinib versus placebo. In the sPGA ≥ 3 subpopulation, sPGA 0/1 was superior with deucravacitinib (51.0% vs 4.3%; <em>P</em> < .0001). Adverse events were comparable between groups.</div></div><div><h3>Limitations</h3><div>16-week analysis.</div></div><div><h3>Conclusion</h3><div>Deucravacitinib was efficacious and well tolerated in patients with moderate to severe scalp psoriasis.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"25 ","pages":"Pages 28-40"},"PeriodicalIF":5.2,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号